Attached files
| file | filename |
|---|---|
| EX-99.1 - PRESS RELEASE - ENDRA Life Sciences Inc. | ndra_ex991.htm |
| EX-10.1 - AMENDMENT 2 TO COLLABORATIVE RESEARCH AGREEMENT - ENDRA Life Sciences Inc. | ndra_ex101.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of
report (Date of earliest event reported): January 30,
2018
|
|
ENDRA
Life Sciences Inc.
|
|
|
|
(Exact
name of registrant as specified in its charter)
|
|
|
|
Delaware
|
|
001-37969
|
|
26-0579295
|
|
|
|
(State
or other jurisdiction
of
incorporation)
|
|
(Commission
File
Number)
|
|
(IRS
Employer
Identification
No.)
|
|
|
|
3600 Green Court, Suite 350, Ann Arbor, MI
|
|
48105
|
|
|
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
|
(Registrant’s
telephone number, including area code): (734) 335-0468
Not Applicable
(Former
name or former address, if changed since last report.)
Check
the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General
Instruction A.2. below):
|
☐
|
Written
communications pursuant to Rule 425 under the Securities Act
(17 CFR 230.425)
|
|
☐
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17
CFR 240.14a-12)
|
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange
Act (17 CFR 240.14d-2(b))
|
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange
Act (17 CFR 240.13e-4(c))
|
Indicate by check
mark whether the registrant is an emerging growth company as
defined in Rule 405 of the Securities Act of 1933 (§230.405 of
this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934
(§240.12b-2 of this chapter).
Emerging growth
company ☑
If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act. ☐
Item
1.01
Entry
into a Material Definitive Agreement
On
January 30, 2018, ENDRA Life Sciences Inc. (the
“Company”) entered into Amendment 2 (the
“Amendment”) to that certain Collaborative Research
Agreement between the Company and General Electric Company
(“GE”), dated as of April 22, 2016 and as amended on
April 21, 2017 (the “Agreement”). The Amendment extends
the term of the Agreement to January 22, 2020.
A copy
of the Amendment is filed herewith as Exhibit 10.1. The foregoing
description is qualified in its entirety by reference to the full
text of the Amendment, which is incorporated herein by
reference.
Item
7.01
Regulation
FD Disclosure
On
February 5, 2018, the Company issued a press release announcing its
entry into the Amendment. A copy of the press release is being
furnished as Exhibit 99.1 to this Current Report on Form
8-K.
The
information furnished in Item 7.01 of this Current Report on
Form 8-K, including Exhibit 99.1 attached hereto, shall
not be deemed “filed” for purposes of Section 18
of the Securities Exchange Act of 1934 (the “Exchange
Act”) or otherwise subject to the liabilities of that
section, nor shall it be deemed incorporated by reference into any
filing under the Securities Act of 1933 or the Exchange Act, except
as expressly set forth by specific reference in such
filing.
Item
9.01
Financial
Statements and Exhibits
The
exhibits required to be filed as a part of this Current Report on
Form 8-K are listed in the Exhibit Index attached hereto and
incorporated herein by reference.
EXHIBIT
INDEX
|
Exhibit
No.
|
|
Description
|
|
|
|
|
|
|
Amendment
2 to Collaborative Research Agreement, dated January 30, 2018, by
and between the Company General Electric Company.
|
|
|
|
Press
Release dated February 5, 2018 issued by the Company, furnished
herewith.
|
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
|
ENDRA Life Sciences Inc.
|
|
|
Date:
February 5, 2018
|
By:
|
/s/
Francois Michelon
|
|
|
Name:
|
Francois
Michelon
|
|
|
Title:
|
Chief
Executive Officer and Director
|